Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform
Streamlined workflow provides earlier visibility into synthesis feasibility, pricing, and fulfillment options.
Press Releases
Ansa Biotechnologies to Showcase Breakthrough DNA Synthesis Technology Backed by Industry’s Only On-Time Guarantee at SynBioBeta 2026 Conference
Direct, sequence-perfect clonal DNA up to 50 kb is empowering customers to expand their design space and innovate without compromise.
Ansa Biotechnologies Appoints Matthias Arenskötter as Chief Operating Officer
Seasoned DNA synthesis executive will oversee expansion of production capacity to meet rising demand for high-quality long and complex DNA products backed by industry’s only service guarantee.
Integrated DNA Technologies Expands Synthetic Biology Portfolio with Ansa Biotechnologies’ Clonal DNA and XL Clonal DNA Products
New collaboration empowers customers with sequence-perfect constructs as long as 50 kb.
Ansa Biotechnologies Appoints Geoff Hamilton as Chief Financial Officer and Chief Business Officer
Mr. Hamilton will lead the company’s financial operations, corporate strategy, and key partnerships as Ansa accelerates its commercial expansion across the biotechnology, synthetic biology, and pharmaceutical sectors.
Ansa Biotechnologies Redefines What’s Possible in DNA Synthesis with 50 kb Sequence-Perfect Clonal Product
Ansa is the first to deliver ultra-long, fully verified DNA in less than 25 days, backed by the industry’s only on-time guarantee. View the press release.
Ansa Biotechnologies Secures $54.4 Million in Series B Financing
Ansa Biotechnologies, Inc. today announced that it has closed $45.2 million and secured commitments for an additional $9.2 million as part of an oversubscribed series B financing round. View the press release.
Ansa Biotechnologies Breaks Traditional Synthetic DNA Length Barriers and Redefines Future of Life Science Research
Ansa Biotechnologies, Inc., the trusted partner for DNA synthesis, today announced the launch of its 50 kb DNA synthesis early access program, providing customers with extremely long and complex DNA sequences in less than four weeks.
Ansa Biotechnologies Sets New Standard in Long, Complex DNA
Combining its complex DNA synthesis platform with a unique long-read sequencing and analysis approach for quality control allows Ansa to produce long, complex DNA more accurately and reliably than any other DNA synthesis vendor. View the press release.
Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products
Ansa Biotechnologies announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments. Ansa is the only company able to synthesize complete, contiguous DNA oligonucleotides as long as 600 bp without requiring assembly, delivering products as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. View the press release.